Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T-cell leukemia virus type I-associated myelopathy/tropical spastic paraparesis

Q4 Medicine IJU Case Reports Pub Date : 2024-08-29 DOI:10.1002/iju5.12773

Tomoyuki Kumekawa, Hidenori Akaihata, Hiroki Natsuya, Yuki Harigane, Hitomi Imai, Kanako Matsuoka, Ryo Tanji, Junya Hata, Soichiro Ogawa, Yoshiyuki Kojima

{"title":"Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T-cell leukemia virus type I-associated myelopathy/tropical spastic paraparesis","authors":"Tomoyuki Kumekawa, Hidenori Akaihata, Hiroki Natsuya, Yuki Harigane, Hitomi Imai, Kanako Matsuoka, Ryo Tanji, Junya Hata, Soichiro Ogawa, Yoshiyuki Kojima","doi":"10.1002/iju5.12773","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Human T-cell lymphotropic virus type 1 infection can cause HTLV-1-associated myelopathy/tropical spastic paraparesis, characterized by spastic paralysis of both lower limbs. More than 90% of HAM/TSP patients show lower urinary tract symptoms and dysfunction.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A 27-year-old woman diagnosed with HAM/TSP presented with overactive bladder. A urodynamic study revealed detrusor overactivity. OAB remained despite improvements in spastic paralysis of the lower limbs after starting prednisolone. The addition of solifenacin likewise failed to improve OAB or DO in this patient. Switching from solifenacin to vibegron improved OAB symptoms.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In patients for whom OAB and DO do not improve with steroid treatment and solifenacin, treatment with vibegron may improve OAB symptoms.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"438-441"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531891/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12773","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Human T-cell lymphotropic virus type 1 infection can cause HTLV-1-associated myelopathy/tropical spastic paraparesis, characterized by spastic paralysis of both lower limbs. More than 90% of HAM/TSP patients show lower urinary tract symptoms and dysfunction.

Case presentation

A 27-year-old woman diagnosed with HAM/TSP presented with overactive bladder. A urodynamic study revealed detrusor overactivity. OAB remained despite improvements in spastic paralysis of the lower limbs after starting prednisolone. The addition of solifenacin likewise failed to improve OAB or DO in this patient. Switching from solifenacin to vibegron improved OAB symptoms.

Conclusion

In patients for whom OAB and DO do not improve with steroid treatment and solifenacin, treatment with vibegron may improve OAB symptoms.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对人类 T 细胞白血病病毒 I 型相关脊髓病/典型痉挛性截瘫引起的神经源性下尿路功能障碍的尿动力学研究结果和 vibegron 效果。

简介人类T细胞淋巴细胞病毒1型感染可导致HTLV-1相关性脊髓病/热带痉挛性瘫痪，其特征是双下肢痉挛性瘫痪。90%以上的HAM/TSP患者会出现下尿路症状和功能障碍：一名被诊断为 HAM/TSP 的 27 岁女性出现膀胱过度活动症。尿动力学检查显示患者有逼尿肌过度活动。尽管开始使用泼尼松龙后下肢痉挛性瘫痪有所改善，但膀胱过度活动症依然存在。添加索利那新同样未能改善该患者的 OAB 或 DO。将索非那新换成维贝琼可改善 OAB 症状：结论：对于接受类固醇治疗和索利那新治疗后 OAB 和 DO 均无改善的患者，使用维贝琼治疗可改善 OAB 症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊